You are here: Home » Current Affairs » Coronavirus » News
Business Standard

J&J likely to apply for EU approval for vaccine in February: Lawmaker

US firm Johnson & Johnson is likely to apply for EU approval for its COVID-19 vaccine candidate in February, a top lawmaker said on Wednesday

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Reuters  |  BRUSSELS 

Coronavirus vaccine

BRUSSELS (Reuters) - U.S. firm Johnson & Johnson is likely to apply for EU approval for its COVID-19 vaccine candidate in February, a top lawmaker said on Wednesday.

"EU Health Commissioner Stella Kyriakides announced during our (EU lawmakers) group meeting this morning that the vaccine manufacturer Johnson & Johnson is likely to submit an application for approval to the EU for their vaccine in February," said Peter Liese, who represents health matters for the EU's centre-right group, the assembly's largest.

The EU drugs regulator had said in December it expected the company to apply in the first quarter of this year.

The European Medicines Agency started on Dec. 1 a rolling review of the vaccine, which Johnson & Johnson is developing through its subsidiary Janssen.

The EU has booked 200 million doses of the J&J vaccine and has an option to order another 200 million shots. The J&J jab is monodose, unlike other vaccines approved so far in the EU and which require two doses for full protection.

 

 

(Reporting by Francesco Guarascio @fraguarascio; editing by Jason Neely and Louise Heavens)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 13 2021. 18:27 IST
RECOMMENDED FOR YOU